BGF has joined the Series A extension for T-Therapeutics, one of the UK’s leading innovators in immune-based drug discovery.

T-Therapeutics, which is developing T cell receptor (TCR) therapeutics for cancer and autoimmune disease, has raised a further £24m as part of the extension, taking the Series A total to date to £70m.

BGF and Tencent joined T-Therapeutics’ existing shareholders in the Series A syndicate, including Sofinnova Partners, F-Prime Capital, Digitalis Ventures, Cambridge Innovation Capital, Sanofi Ventures and the University of Cambridge Venture Fund.